Introduction
============

*Staphylococcus aureus* multi-resistant to antibiotics is a leading cause of bacterial infections in hospitals and communities. Specifically, methicillin-resistant *S. aureus* (MRSA) has spread worldwide in the second half of the 20th century and is now considered endemic in healthcare facilities in all industrialized countries ([@B22]). In 2005 livestock-associated MRSA (LA-MRSA) emerged in pigs ([@B4]), where it plays an important role a reservoir of infection to humans ([@B14]). It was later reported in different farm animals, including horses, cattle or poultry worldwide ([@B18]; [@B2]). *S. aureus* frequently infects commercial rabbits ([@B8]), but there is only one reported case in which LA-MRSA was identified in this animal species, and was also isolated from farmers and their relatives ([@B1]).

The results of population genetics studies have shown that most *S. aureus* strains are host-specific, which indicates low frequency of cross-species transmission ([@B13]). However, more recent studies that employed the multilocus sequence typing (MLST) have identified several sequence types (ST) that are associated with multiple host species. This finding implies either zoonotic transmission or a recent common ancestor ([@B33]).

Several *S. aureus* MLST lineages have been associated with animals, including clonal complexes (CC): CC1 (livestock), CC5 (avian), CC130 (multi-host), CC133 (ruminants), CC151 (ruminants), CC398 (livestock), and CC425 (ruminants and wild mammals) ([@B20]). *S. aureus* CC121 has a multi-host tropism ([@B39]), including humans, where it is considered a globally disseminated hypervirulent clone, although 90% of ST121 strains are methicillin-sensitive ([@B31]). In commercial rabbits, ST121 is by far the most frequently isolated clone, with prevalences close to, and even higher than, 90% ([@B41]; [@B19]). This causes important economic loss associated with several lesions, such as mastitis, multisystemic abscessation and pododermatitis ([@B8]). However, no information in rabbits about the susceptibility of ST121 strains to methicillin is available.

Due to the increasing presence of LA-MRSA strains in different animal species and the scarcity of available information on commercial rabbits, the aims of this study were to: (i) evaluate the presence of MRSA in a *S. aureus* collection obtained from staphylococcal lesions on different Spanish and Portuguese rabbit farms; (ii) compare the isolated strains using MLST, SCC*mec*, and *agr* typing; (iii) determine antibiotic resistance profile and virulence factors.

Materials and Methods {#s1}
=====================

Isolation and Characterization of *S. aureus* Isolates
------------------------------------------------------

Two hundred and forty *S. aureus* isolates from rabbit clinical samples obtained on 89 rabbitries located in Spain (*n* = 82) and Portugal (*n* = 7), were studied in our laboratories in the last 4 years (2014--2017). These selected samples came from rabbits with different lesion types, including mastitis (*n* = 86), subcutaneous abscesses (*n* = 33), pododermatitis (*n* = 31), dermatitis (*n* = 21), otitis (*n* = 13), metritis (*n* = 12), conjunctivitis (*n* = 11), pneumonia (*n* = 9), rhinitis (*n* = 3), hepatitis (*n* = 3), peritonitis (*n* = 2), pericarditis (*n* = 1), and osteomyelitis (*n* = 1). Fourteen *S. aureus* isolates from nasal carriers were also analyzed.

Samples were inoculated on blood-agar (BioMérieux, Marcy l'Etoile, France) and incubated aerobically at 37°C for 24--48 h. *S. aureus* strains were identified on the basis of morphological growth characteristics and hemolytic properties ([@B9]). To perform PCR, genomic DNA was extracted from each isolate with a Genelute Bacterial Genomic DNA kit (Sigma), according to the manufacturer's protocol, except for bacterial cells, which were lysed by lysostaphin (12.5 μg/ml, Sigma) at 37°C for 1 h before DNA purification. Isolates were genotyped by MLST ([@B11]).

All the strains were checked for the presence of the *mec*A/*mec*C genes by PCR, as previously described ([@B16]; [@B21]). Furthermore, SCC *mec* cassette element classification was carried out for all the *mec*A-positive isolates, as described elsewhere ([@B44]; [@B28]).

Detection *chp*, *sak*, *sea*, *sep*, *scn*, *tst,* and *PVL*-Encoding Genes and *agr* Typing
---------------------------------------------------------------------------------------------

The MRSA isolates were subjected to a PCR assay to detect the *lukF/S-PV* genes that encode the PVL toxin and the *tst* gene that encodes the TSST-1 toxin and *agr* typing, as previously described ([@B40]). These strains were also checked for the presence of the immune-evasion cluster (IEC) genes (*sea*, *sep*, *sak*, *chp*, and *scn*) by PCR, as formerly described ([@B37]).

Antibiotic Susceptibility Testing
---------------------------------

The antibiotic susceptibility of the MRSA isolates was determined by the disk diffusion method on Mueller-Hinton agar (MHA, CONDA, Spain), according to the recommendations of the Clinical and Laboratory Standards Institute (CLSI). The disk diffusion assay was done with 14 antibiotics: bacitracin (10 U), enrofloxacin (5 μg) (OXOID), streptomycin (10 μg), spiramycin (100 μg), sulfadiazine (25 μg), chloramphenicol (30 μg) (BD), doxycycline (30 μg), erythromycin (15 μg), gentamicin (10 μg), neomycin (30 μg), penicillin (10 U), tetracycline (30 μg), cefoxitin (30 μg), and trimethoprim/sulfamethoxazole (1.25 μg/23.75 μg, respectively) (BIO-RAD). Minimum inhibitory concentrations (MIC) for cefoxitin and vancomycin was determined by using MIC Test Strip (Liofilchem) on inoculated Mueller Hinton agar plates and the results were interpreted according EUCAST breakpoints. *S. aureus* strain ATCC 25923 and *Enterococcus faecalis* strain ATCC 29212 were used as controls in the susceptibility test.

Statistical Analysis
--------------------

Categorical data were compared using Fisher exact test. All reported *p*-values are two-tailed and analyses were performed using GraphPad software.^[1](#fn01){ref-type="fn"}^ Variables with *p* \< 0.01 were considered to be statistically significant.

Results
=======

Identification of MRSA and Lesions
----------------------------------

Of all the analyzed *S. aureus* isolates, 12.5% (30/240) were identified as methicillin-resistant. Of the 30 MRSA isolates, *mec*A was detected in 27 isolates. In 3 isolates *mec*C were amplified. The 30 isolates were cefoxitin-resistant, with inhibition zone diameters \<22 mm (range 0--20 mm) using disk diffusion method and MIC values \>4 μg/ml (range 8--256 μg/ml).

When considering lesion type, MRSA was most frequently present in hepatitis samples (100%, 3/3), followed by metritis (58.3%, 7/12), pneumonia (44.4%, 4/9), rhinitis (33.3%, 1/3), otitis (23.1%, 3/13), conjunctivitis (18.2%, 2/11), mastitis (9.3%, 8/86), dermatitis (4.8%, 1/21), and pododermatitis (3.2%, 1/31). Hepatitis and metritis were strongly associated with MRSA (*p* \< 0.0001) (see **Table [1](#T1){ref-type="table"}**). When only the commonest lesions (mastitis, abscesses, and pododermatitis) were taken into account, MRSA was identified in 6% (9/150) of the cases. None of the 14 isolates from nasal carriers were MRSA.

###### 

Number of MRSA and MSSA isolates identified from different lesions.

  Lesion           No. isolates   MRSA     MSSA      *p-*value
  ---------------- -------------- -------- --------- ------------
  Mastitis         86             8        78        0.3127
  Abscess          33             --       33        0.0192
  Pododermatitis   31             1        30        0.1422
  Dermatitis       21             1        20        0.4867
  Otitis           13             3        10        0.2120
  Metritis         12             7        5         **0.0001**
  Conjunctivitis   11             2        9         0.6328
  Pneumonia        9              4        5         0.0162
  Rhinitis         3              1        2         0.3313
  Hepatitis        3              3        0         **0.0018**
  Peritonitis      2              --       2         1
  Pericarditis     1              --       1         1
  Osteomyelitis    1              --       1         1
  Nasal carrier    14             --       14        0.2270
  **Total**        **240**        **30**   **210**   
                                                     

Bolded values indicate variables with p \< 0.01 were considered to be statistically significant.

Characterization of *S. aureus* Isolates
----------------------------------------

The MLST typing analysis revealed 13 different STs. The MLST type, including the largest number of isolates, was ST121 (*n* = 73). This was immediately followed by ST3764 (*n* = 57), ST96 (*n* = 36), ST2855 (*n* = 32), and ST1 (*n* = 13). Other less frequent STs were ST398 (*n* = 11), ST146 (*n* = 6), ST5 (*n* = 4), ST3761 (*n* = 3), ST4774 (*n* = 2), a novel *tpi* single locus variant of ST130, ST4473 (*n* = 1), a novel *arc* single locus variant of ST4470, ST407 (*n* = 1), and ST3759 (*n* = 1).

The 30 MRSA isolates from 22 farms (15 Spanish and 7 Portuguese) belonged to ST2855 (53.3%, 16/30), ST146 (20%, 6/30), ST398 (20%, 6/30), and ST4774 (6.6%, 2/30). For SCC*mec* typing, the multiplex PCR assay identified 15 of the 27 *mec*A MRSA isolates with SCC*mec* type III, 6 with SCC*mec* type IV, and 6 with SCC*mec* type V. The 3 *mec*C MRSA isolates belonged to a ST4774 and one ST2855.

All the MRSA strains belonging to the same lineage displayed an identical accessory gene regulator (*agr*) type and SCC*mec*-type: ST2855 harbored *agr*III and SCC*mec*-type III; ST146 displayed *agr*II and SCC*mec*-type IV; ST398 contained *agr*I and SCC*mec*-type V; ST4774 harbored *agr*III (**Table [2](#T2){ref-type="table"}**). Methicillin-susceptible *S. aureus* (MSSA) strains with *agr* type I belonged to lineage ST398 and ST407; ST5 and ST3759 harbored *agr*II; ST1, ST96, ST2855, and ST4473 displayed *agr*III; ST121, ST3764, and ST3761 contained *agr*IV.

###### 

Relationship among the type of lesions and genotypic (MLST, SCC*mec*, *agr* and IEC types) and phenotypic (antibiotic profile) characteristics in the MRSA isolates.

  Isolate ID   Lesion                  Genotypic characteristics   MIC (μg/ml)   Phenotypic resistance profile^∗^                
  ------------ ---------------- ------ --------------------------- ------------- ---------------------------------- ----- ------ --------------------
  Sp-794       Otitis           146    IV                          II            E                                  32    0.75   ENO-N-TET
  Sp-795       Otitis           146    IV                          II            E                                  24    1.5    ENO-N-TET
  Sp-986       Dermatitis       146    IV                          II            E                                  48    1.5    N-TET
  Sp-992       Otitis           146    IV                          II            E                                  48    1.5    ENO-S-N-TET
  Sp-1004      Pneumonia        146    IV                          II            E                                  48    1.5    ENO-N-TET
  Sp-1005      Pneumonia        146    IV                          II            E                                  48    2      ENO-S-N
  Sp-1006      Conjunctivitis   398    V                           I             --                                 16    0.75   CN-TET
  Sp-1007      Rhinitis         398    V                           I             --                                 12    1      ENO-E-SPC-TET
  Sp-1008      Mastitis         398    V                           I             --                                 16    0.75   DO-ENO-E-SPC-TET
  Sp-1018      Mastitis         398    V                           I             --                                 12    0.75   ENO-E-SPC-CN-TET
  Sp-1019      Conjunctivitis   398    V                           I             --                                 12    0.75   ENO-E-SPC-CN-TET
  Sp-1032      Mastitis         398    V                           I             --                                 12    0.75   ENO-S-TET
  P-988        Metritis         2855   III                         III           --                                 16    1.5    S-TET
  P-989        Mastitis         2855   III                         III           --                                 32    1.5    ENO-E-SPC-S
  Sp-990       Pneumonia        2855   III                         III           --                                 32    1.5    ENO-E-SPC-S-TET
  P-991        Metritis         2855   III                         III           --                                 32    1.5    ENO-E-SPC-S-TET
  Sp-993       Mastitis         2855   III                         III           --                                 16    1.5    S
  P-994        Pododermatitis   2855   III                         III           --                                 32    1      C-ENO-E-SPC-TET
  P-995        Hepatitis        2855   III                         III           --                                 48    1.5    ENO-S-N
  P-996        Mastitis         2855   III                         III           --                                 32    2      ENO-E-SPC-S-TET
  P-997        Mastitis         2855   III                         III           --                                 48    2      DO-ENO-E-SPC-S-TET
  P-998        Metritis         2855   III                         III           --                                 32    1      DO-E-SPC-TET
  Sp-1000      Metritis         2855   III                         III           --                                 48    2      ENO-E-SPC-S-TET
  Sp-1001      Hepatitis        2855   III                         III           --                                 256   1.5    ENO-E-S-TET
  Sp-1002      Metritis         2855   III                         III           --                                 32    1.5    ENO-E-SPC-S-TET
  P-1003       Hepatitis        2855   III                         III           --                                 64    2      DO-E-SPC-S-TET
  P-1009       Pneumonia        2855   III                         III           --                                 48    2      CN-TET
  P-985        Metritis         2855   *mec*C                      III           --                                 12    1.5    C-ENO -E-SPC-S
  Sp-987       Metritis         4774   *mec*C                      III           --                                 8     1      ENO-E-SPC-S-TET
  Sp-999       Mastitis         4774   *mec*C                      III           --                                 12    1.5    ENO-E-SPC-TET
                                                                                                                                 

∗

All MRSA strains were resistant to cefoxitin and penicillin and susceptible sulfonamides (sulfadiazine and trimethoprim/sulfamethoxazole) and bacitracin. C, chloramphenicol; CN, gentamicin; DO, doxycycline; E, erythromycin; ENO, enrofloxacin; FOX, cefoxitin; MIC, Minimum inhibitory concentrations; N, neomycin; P, Portugal; S, streptomycin; Sp, Spain; SPC, spiramycin; TET, tetracycline; VAN, vancomycin.

Antibiotic Resistance Profile
-----------------------------

The full resistance rates among the 30 MRSA isolates tested in the present study were as follows: 100% (*n* = 30) for cefoxitin and penicillin, 83.3% (*n* = 25) for tetracycline, 76.6% (*n* = 23) for enrofloxacin, 60% (*n* = 18) for erythromycin, 56.6% (*n* = 17) for streptomycin and spiramycin, 23.3% (*n* = 7) for neomycin, 13.3% (*n* = 4) for doxycycline and gentamicin and 6.6% (*n* = 2) for chloramphenicol. Conversely, all the tested isolates were susceptible to sulfonamides (sulfadiazine and trimethoprim/sulfamethoxazole) and bacitracin.

The majority of the tested MRSA isolates (*n* = 29, 96.6%) were multidrug-resistant (resistant to three antimicrobial classes or more). A comparison of occurrence of antimicrobial resistance among the investigated MRSA isolates in relation to different STs is presented in **Table [2](#T2){ref-type="table"}**. The ST2855 strains showed resistance to a larger number of antibiotic groups than other MRSA strains; specifically to tetracycline, macrolides (erythromycin and spiramycin) and enrofloxacin. The highest percentage of tetracyclines (100%) resistance was recorded among the ST398 strains. ST146 isolates showed resistance to a smaller number of antibiotics, of which neomycin (100%), enrofloxacin (83.3%), and tetracycline (83.3%) stood out. The two ST4774 isolates showed resistance to enrofloxacin, macrolides, and tetracycline (100%) and in one case also to streptomycin. For the remaining antimicrobial groups, no differences in resistance were observed among the STs. MIC Test Strip for cefoxitin detect a strain ST2855 with high level resistance (MIC, 256 μg/ml). None of the MRSA isolates showed resistance to vancomycin, with MICs ranged from 0.5 to 2 μg/ml.

Detection of IEC Cluster (*scn*, *chp*, *sak*, and *sea* or *sep*), *tst*, and PVL Genes Among MRSA Isolates
------------------------------------------------------------------------------------------------------------

The PCR detection of the IEC genes, *tst* and PVL-encoding genes was carried out for the MRSA isolates. None of the MRSA isolates were positive for *sea* or *sep*, *chp*, *tst,* and PVL genes. The *sea*/*sep* gene along with the *sak* (73.3%), *chp* (0%), and *scn* (20%) genes, modulators of different parts of the innate immune system, forming an immune evasion cluster (IEC) ([@B37]). Depending on the presence or absence of these genes and their different combinations, *S. aureus* isolates were classified into 7 different IEC types according to patters previously described. The *scn* gene is mandatory for the consideration of the IEC types ([@B6]). All ST146 isolates contained IEC type E (comprised of *sak* and *scn* genes). However, isolates belonging to ST2855 were associated with the presence only of the *sak* gene, while the strains belonging to ST398 and ST4774 did not contain IEC genes.

Discussion
==========

In the present study, 240 *S. aureus* isolates obtained from rabbits suffering different lesions, located on 89 farms of Spain and Portugal, were analyzed between 2014 and 2017. Isolates were obtained mainly from mastitis (*n* = 86), abscesses (*n* = 33) and pododermatitis (*n* = 31), which were the most frequently observed lesions associated with *S. aureus* infections in commercial rabbits ([@B32]; [@B42]).

Screening for methicillin-resistant isolates allowed the identification of 30 strains as MRSA. The lesion types from which they were isolated differed compared with those upper previously indicated as more frequent (mastitis, abscesses, and pododermatitis). MRSA was detected in 100% (3 out of 3) of hepatitis cases, metritis (58.3%, 7/12), pneumonia (44.4%, 4/9), rhinitis (33.3%, 1/3), otitis (23.1%, 3/13), conjunctivitis (18.2%, 2/11), mastitis (9.3%, 8/86), dermatitis (4.8%, 1/21), and pododermatitis (3.2%, 1/31). Therefore, while the percentage of the most frequent lesions (mastitis, abscesses, and pododermatitis) caused by *S. aureus* was 62.5% of all lesions (150/240), MRSA was involved only in 30% (9/30) of these same lesions. They were not isolated from abscesses and there was only one pododermatitis case. Hepatitis and metritis were found to be strongly associated with MRSA (hepatitis *p* \< 0.0018; metritis *p* \< 0.0001). This unusual lesion pattern occasioned with MRSA strains *versus* habitual *S. aureus* infections could indicate a different pathogenesis of MRSA infections in rabbits.

In order to understand the pathogenesis of staphylococcal infections, the correct identification of the involved strain is vital. Thus the development of high discriminatory typing techniques, such as MLST, is very important ([@B11]). In the present study, the most frequently detected MLST type was ST121 (73/240). It has been reported that the majority of chronic staphylococcal infections in rabbits are caused by high virulence strains that belong mainly to the ST121 lineage ([@B38]; [@B41]; [@B19]). The ST121 lineage was also the predominant one in this study, followed immediately by ST3764 (57/240). This last lineage, together with strains ST3761, a minority in our study (*n* = 3), belong to clonal complex CC121. *S. aureus* CC121 has a multi-host tropism, which is a common cause of human skin and soft-tissue infections ([@B39]). In humans, the ST121 lineage is also considered a hypervirulent clone, although approximately 90% of the ST121 strains were methicillin-sensitive ([@B31]). The present study agrees with these results since all the ST121 strains from rabbit isolates were methicillin-sensitive.

A further ten different ST types among the tested isolates were identified: ST96 (*n* = 36), ST2855 (*n* = 32), ST1 (*n* = 13), ST398 (*n* = 11), ST146 (*n* = 6), ST5 (*n* = 4), ST4774 (*n* = 2), ST4473 (*n* = 1), ST407 (*n* = 1), and ST3759 (*n* = 1). However, MRSA isolates showed limited genetic diversity (ST2855, ST146, ST398, and ST4774), being the ST2855 the most predominant clone (53.3%; 16/30). It is noteworthy that 50% (16/32) of strains ST2855 were methicillin-sensitive. The only isolate described to date to belong to this lineage is an MSSA isolate of mastitis, described in a rabbit from Italy in 2012.^[2](#fn02){ref-type="fn"}^ All the ST146 strains isolated herein were methicillin-resistant. No data exists in the literature about *S. aureus* isolates from rabbits that belong to this lineage. ST146 belongs to clonal complex CC5. This clonal complex has been previously found in *S. aureus* isolates from rabbit carcasses, but none were methicillin-resistant ([@B27]). *S. aureus* associated with CC5 is commonly detected in humans or animal hosts, including poultry ([@B24]). On the other hand, six of the 11 ST398 isolates were MRSA. The only LA-MRSA case to have occurred in rabbits for meat production belongs to this lineage ([@B1]). Finally, the 3 *mec*C MRSA isolates belonged to ST4774, a novel *tpi* single locus variant of ST130, and one ST2855. Isolates reported to date and carrying *mec*C belonged mainly to lineages common in cattle, namely CC130, CC1943, and CC425, suggesting a zoonotic reservoir ([@B2]). Besides cattle, *mec*C has also been found among other farm animals such isolates ST130 in sheep ([@B3]; [@B17]) and an isolate ST425 that caused a highly virulent infection in a rabbit ([@B30]).

Other typing techniques used to characterize MRSA strains include the identification of the *agr* and staphylococcal cassette chromosome *mec* (SCC*mec*). The *mec*A-positive MRSA strains that belong to the same lineage displayed identical *agr* and *mec* types: ST2855 harbored *agr*III and *mec* type III; ST146 displayed *agr*II and *mec* type IV and ST398 contained *agr*I and *mec* type V. The *mec*C-positive isolates harbored *agr*III. The *agr* locus plays a critical role in MRSA pathogenesis and has been assumed to play a key role in human staphylococcal infections ([@B10]). Other lineages with *agr*III include strains type ST96 or ST1. In rabbits, differences have been detected in the virulence between strains ST121 and ST96 ([@B19]; [@B40]), which could be related with differences with this regulator type. Regarding the SCC*mec* type, different combinations of genes in several SCC*mec* types also leads to the strains displaying distinct antibiotic susceptibilities. Although the majority of the tested MRSA isolates were multidrug-resistant, the ST2855 strains showed resistance to a larger number of antibiotic groups than other strains, as well as higher frequency of resistance to macrolides. This multiresistance could justify its more extended presence compared to other MRSA strains. Types II and III SCC*mec* segments have been reported to be longer and to possess multidrug resistances to the strains that carry these elements. These types have frequently been demonstrated in HA-MRSA strains ([@B36]). Similarly to other studies, the ST398 strains identified in this study belonged to V SCC*mec* type ([@B43]; [@B5]). The highest percentage of tetracyclines (100%) resistance were recorded among the ST398 strains. Resistance to tetracycline is also associated with LA ST398 ([@B20]), and acquisition of *tet*K as part of SCC*mec* type Vc by *tet*M-positive LA ST398 has been demonstrated ([@B25]). On the other hand, ST146 isolates showed resistance to fewer antibiotics, of which neomycin (100%), enrofloxacin (83.3%) and tetracycline (83.3%) stand out. In Spain, ST146 MRSA has been detected in nasal carriage in Primary Healthcare Center patients. This isolate was typed as ST146-CC5 SCC*mec* IVc, and it presented a multiresistance phenotype, similarly to our ST146 rabbit strains. Strains with similar characteristics are considered hospital-acquired HA-MRSA ([@B26]). Finally, *mec*C is part of a novel SCC*mec* assigned type XI ([@B15]). [@B2] describes that isolates of this new genetic element are not resistant to antibiotics other than beta-lactams, in contrast to our results where *mec*C strains also showed resistance to enrofloxacin, tetracycline and macrolides.

Finally, all the MRSA strains described in this study were negative for the genes that code toxins PVL and TSST-1. A comparative analysis of the accessory genomes of the ST121 strains showed that the majority of human strains contained mobile genetic elements, which encode the potent toxins involved in human disease pathogenesis, such as PVL and TSST-1. According to our study, no rabbit strains carried *luk*S/F-PV or *tst* genes, which indicates that they are dispensable for the *S. aureus* infection of rabbits ([@B39]). On the other hand, the presence of the immune-evasion-cluster (IEC) genes was determined for MRSA isolates to determine whether they may have human or animal origin. The presence of IEC type E in all ST146 isolates points to the possible human origin of this clone. However, ST398 and ST4774 (a single locus variant of ST130) isolates belonging to LA-lineages since were IEC negative. There are numerous reports of the presence of LA-MRSA in livestock caused by CC398 and several MRSA lineages as CC130 ([@B1]; [@B29]; [@B2]; [@B20]). However, isolates belonging to ST2855 were associated with the presence only of the *sak* gene. [@B34] described the presence of IEC in a porcine *S. aureus* CC398 isolate within the livestock clade, which supports that reacquisition of IEC enables LA-MRSA CC398 to spread in human populations. More recently [@B23] demonstrated that lysogenic conversion of LA-CC398 strains by virulence-associated phages may occur and that new pathotypes may emerge by this mechanism.

Vancomycin is an important antibiotic to treat MRSA isolates, so the emergence of vancomycin-resistant *S. aureus* (VRSA) strains poses a serious global threat to public health. Two mechanisms, including cell wall changes and acquired *van* genes were involved in vancomycin resistance. None of the MRSA isolates showed resistance to vancomycin.

A cefoxitin disk diffusion test is used to predict the presence of *mec*A in *S. aureus* ([@B7]; [@B35]). All MRSA isolates were cefoxitin-resistant, with inhibition zone diameters \<22 mm using disk diffusion method. Therefore, this method is a good test for routine detection of all classes of MRSA. On the other hand, isolates harboring *mec*C typically yield negative results for conventional *mec*A PCR, which can translate in detection errors in a subset of MRSA isolates ([@B30]). Therefore, detecting *mec*A/*mec*C genes proves to be more reliable test for detecting methicillin resistance among staphylococci.

Methicillin-resistant *S. aureus* prevalence varies according to sampling type and the studied animal species. The [@B12] has reported a 26.9% MRSA prevalence, which was detected in the dust of pigs' production holdings of the European Union. Recent research into small ruminants has indicated an overall estimated prevalence of 0.70% (2/286) in milk samples in herds ([@B17]). In cattle a 4.4% prevalence has been reported in isolates collected from bovine mastitis cases ([@B5]). In the only MRSA case published in rabbits, only in 1 of 40 (2.5%) farms with clinical staphylococcosis has detected MRSA in skin samples ([@B1]). Although the present study was not designed according to an epidemiological point of view, an unexpectedly large number of positive samples (12.5%; 30 of 240 isolates) from 22 different farms (22 of 89 farms) in Spain (*n* = 15) and Portugal (*n* = 7) was detected. Therefore, it can be stated that the spread of MRSA strains on Spanish and Portuguese rabbitries in the last 4 years is worrisome.

Conclusion
==========

An unexpected large number of MRSA strains obtained from numerous rabbit farms, isolated from infrequent lesions in *S. aureus* infections, is herein reported. A new lineage of MRSA, ST2855 associated with livestock, has not yet been described. This is the first description of LA-MRSA in rabbits belonging to ST2855 and the first report of *mec*C MRSA in rabbit samples from Iberian Peninsula. More studies are needed to further characterize these isolates and their relationship with humans and other species.

Ethics Statement
================

No approval from the Animal Welfare Ethics Committee was required, since all isolates were analyzed as part of microbiological diagnostics in accordance with the Spanish law RD53/2013.

Author Contributions
====================

JC and LS conceived the presented idea. EM-G, SP-F, and AM-S carried out the experiments. AF-R and CS-T contributed to samples preparations. LS wrote the manuscript with support from DV and JC. All authors discussed the results and contributed to the final manuscript.

Conflict of Interest Statement
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding.** This study has been supported by grants from the Universidad CEU Cardenal Herrera (INDI 17/07) and the Comisión Interministerial de Ciencia y Tecnología (AGL2014-53405-C2-2-P). Grants for SP-F from the Generalitat Valenciana (ACIF/2016/085), and for AM-S and EM-G from the Universidad CEU Cardenal Herrera, are also gratefully acknowledged.

<https://www.graphpad.com/quickcalcs/catMenu/>

<https://pubmlst.org/saureus/>

[^1]: Edited by: Muna Anjum, Animal and Plant Health Agency, United Kingdom

[^2]: Reviewed by: Ákos Tóth, National Public Health Institute (OKI), Hungary; Pierluigi Di Ciccio, Università degli Studi di Torino, Italy

[^3]: ^†^These authors have contributed equally to this work

[^4]: This article was submitted to Antimicrobials, Resistance and Chemotherapy, a section of the journal Frontiers in Microbiology
